gov.uk Main News

Related News

Flu and COVID-19 surveillance report published - gov.uk
gov.uk
44%
388
Flu and COVID-19 surveillance report published
.COVID-19 activity remained stable.SARS-CoV-2 positivity remained stable at 3.7% in week 11 compared to 3.7% in the previous week. This is based on a percentage of people who test positive among those with symptoms tested at sentinel “spotter” laboratories, reported through the Respiratory DataMart surveillance system.COVID-19 case rates and positivity in Pillar 1 decreased overall and within some age, ethnic groups, and regions in week 11.Through the SIREN healthcare cohort study, the SARS-CoV-2 positivity increased in week 11 compared to the previous week.COVID-19 hospitalisations increased slightly to 1.85 per 100,000 compared to 1.76 per 100,000 in the previous week.COVID-19 ICU admissions remained low and stable at 0.06 per 100,000 in week 11.The total number of confirmed COVID-19 acute respiratory incidents decreased compared to the previous week, with 5 incidents reported in England during week 11.The highest hospital admission rate is currently in the North East at 3.44 per 100,000.Those aged 85 years and over had the highest hospital admission rate, which increased to 21.45 per 100,000, with most of the remaining age groups remaining stable.Details of the Spring 2024 COVID-19 vaccination programme will be confirmed soon by NHS England, which will be offered to those who are aged 75 years and over, residents in a care home for older adults and individuals aged 6 months and over who are immunosuppressed.Influenza activity remained stable.Influenza positivity increased slightly to 5.9% in week 11 compared to 5.3% in the previous week.
Clinical platform trials for coronavirus (COVID-19) treatments - gov.uk - Britain
gov.uk
78%
749
Clinical platform trials for coronavirus (COVID-19) treatments
, the COVID-19 Antivirals and Therapeutics Taskforce closed on 31 March 2023.Find out more about on the National Institute for Health and Care Research (NIHR) website.Find out more about on the NHS website.Clinical trials are essential to finding new and improved methods of treating different diseases including coronavirus (COVID-19).Clinical trials allow us to understand whether new treatments:Phase 1 and 2 trials are early-stage trials involving small numbers of participants to ensure a treatment is safe to use and shows evidence of a benefit beyond the standard of care.Treatments that are found to be safe at this stage may then proceed to be tested in a phase 3 clinical trial.Phase 3 trials involve large numbers of patients and assess whether a treatment is effective enough to be used more widely in the NHS.The National Institute for Health and Care Research (NIHR) established a single UK-wide process to prioritise COVID-19 research as Urgent Public Health research early in the COVID-19 pandemic. The purpose was to:The COVID-19 Antivirals and Therapeutics Taskforce worked with NIHR and other partners to horizon scan and monitor national and international developments in COVID-19 antivirals and therapeutics.The Department of Health and Social Care (DHSC) is continuing to support a series of national clinical trial ‘platforms’ across all phases of human trials and in a range of patient cohorts.
Regulatory approval of Pfizer/BioNTech vaccine for COVID-19 - gov.uk
gov.uk
76%
994
Regulatory approval of Pfizer/BioNTech vaccine for COVID-19
PDF, 165 KB, 34 pagesThis file may not be suitable for users of assistive technology.PDF, 109 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 139 KB, 28 pagesThis file may not be suitable for users of assistive technology.PDF, 110 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 137 KB, 27 pagesThis file may not be suitable for users of assistive technology.PDF, 109 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 128 KB, 27 pagesThis file may not be suitable for users of assistive technology.PDF, 108 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 118 KB, 24 pagesThis file may not be suitable for users of assistive technology.PDF, 136 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 105 KB, 22 pagesPDF, 120 KB, 7 pagesHTMLPDF, 4.12 MB, 74 pagesHTMLPDF, 540 KB, 18 pagesHTMLPDF, 130 KB, 5 pagesHTMLPDF, 163 KB, 7 pagesThe 15-minute observation period following vaccination with COVID-19 Vaccine Pfizer/BioNTech or Moderna has been removed for individuals aged 12 years and over who have no history of a severe allergic reaction (as outlined in the .) This follows careful review of the safety data by the MHRA and advice from the government’s independent Commission on Human Medicines. A temporary suspension of the 15-minute observation period for children aged 5-11 years remains in place and this will be reviewed on a regular basis.
COVID-19 vaccination: consent forms and letters for care home residents - gov.uk
gov.uk
89%
259
COVID-19 vaccination: consent forms and letters for care home residents
PDF, 52.1 KB, 1 pageThis file may not be suitable for users of assistive technology.ODT, 27.1 KB This file is in an format This file may not be suitable for users of assistive technology.MS Word Document, 134 KBThis file may not be suitable for users of assistive technology.ODT, 22.1 KB This file is in an format This file may not be suitable for users of assistive technology.MS Word Document, 35.3 KBThis file may not be suitable for users of assistive technology.Ref: PHE gateway number 2020367PDF, 52.3 KB, 1 pageThis file may not be suitable for users of assistive technology.ODT, 27.7 KB This file is in an format This file may not be suitable for users of assistive technology.MS Word Document, 134 KBThis file may not be suitable for users of assistive technology.ODT, 22.6 KB This file is in an format This file may not be suitable for users of assistive technology.MS Word Document, 37.2 KBThis file may not be suitable for users of assistive technology.Ref: PHE gateway number 2020368PDF, 52.6 KB, 1 pageThis file may not be suitable for users of assistive technology.ODT, 28.3 KB This file is in an format This file may not be suitable for users of assistive technology.MS Word Document, 136 KBThis file may not be suitable for users of assistive technology.ODT, 23 KB This file is in an format This file may not be suitable for users of assistive technology.MS Word Document, 36.3 KBThis file may not be suitable for users of assistive technology.When considering a decision made in someone’s best interests, the past views of the person should be taken into account.
COVID-19: the green book, chapter 14a - gov.uk
gov.uk
57%
739
COVID-19: the green book, chapter 14a
PDF, 746 KB, 57 pagesThis file may not be suitable for users of assistive technology.This chapter includes information on:Updated mention of a table.Updated to include JCVI advice on vaccination for children aged 6 months to 4 years in a clinical risk group.Updated storage information for VidPrevtyn.Updated to include shortened background, separation between the historical pandemic response and the ongoing programme, spring booster campaign, explanation of the end of universal primary and booster offers, and describing the move to only offer vaccine during seasonal campaigns.Updated to include approval of Pfizer bivalent vaccine and further clarification around vaccination of under 12 year olds.Updated to include information on the autumn programme and variant vaccines, and further clarification of information on revaccination and capillary leak syndrome.Updated to include: approval of Novavax, clarification around deferral after COVID-19 infection, one-off programme for 5 to 11 year olds who are not in clinical risk groups, advice on use of the paediatric formulation in those aged 12 years, spring booster recommendations (including flexibility around timing) and expectations for an autumn booster, clarification of the management of individuals with a history of allergic reactions, updated advice on management of people who have ITP following vaccination.Updated background to include latest data on vaccine effectiveness and booster safety; clarified and corrected chronology of booster advice.
Coronavirus (COVID-19): right to work checks - gov.uk - Britain - Ireland
gov.uk
83%
687
Coronavirus (COVID-19): right to work checks
.Deferring the end date ensured that employers had sufficient time to develop commercial relationships with identity service providers, make the necessary changes to their pre-employment checking processes and carry out responsible on-boarding of their chosen provider.It has also ensured that the right to work scheme has continued to support long-term, post-pandemic working practices, providing sufficient time to put measures in place to enable face to face document checks if employers do not wish to adopt digital checks for British and Irish citizens with a valid passport (or Irish passport card).From 1 October 2022, employers must carry out one of the prescribed checks before employment commences, as set out in guidance.These checks are:a manual right to work checka right to work check using IDVT through the services of an identity service provider (IDSP)a Home Office online right to work checkConducting any of these checks will provide employers with a statutory excuse which is a defence against a civil penalty.Further information for employers on how to conduct these checks is available on the .Where a right to work check has been conducted using the , the information is provided in real time directly from Home Office systems and there is no requirement for employers to see or check the individual’s documents.Employers cannot insist individuals use this service or discriminate against those who choose to use accepted documents to prove their right to work.The has a list of acceptable documents.Employers do not need to carry out retrospective checks on those who had a COVID-19 adjusted check between 30 March 2020 and 30 September 2022 (inclusive).
DMCA